Latest Hotspot

Merck Initiates Phase 3 Trial for Bomedemstat in Select Essential Thrombocythemia Cases

30 August 2024
3 min read

Merck (NYSE: MRK), also known as MSD outside of the U.S. and Canada, has announced the launch of Shorespan-007, a critical Phase 3 clinical study focused on assessing the efficacy of bomedemstat. Bomedemstat is an experimental oral lysine-specific demethylase 1 (LSD1) inhibitor being studied for use in treating patients with essential thrombocythemia (ET) who have not previously undergone cytoreductive therapy. Essential thrombocythemia is a chronic and rare blood disorder, and it is the most prevalent subtype of myeloproliferative neoplasm. The Shorespan-007 trial has commenced with patient recruitment happening worldwide.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

"The care standard for essential thrombocythemia has not changed for decades, and patients are seeking new treatments that can enhance both disease management and quality of life," stated Dr. Gregory Lubiniecki, vice president of global clinical development at Merck Research Laboratories. "We are swiftly progressing our clinical development initiatives with the aim of addressing these unmet needs and providing additional options to those affected by myeloproliferative neoplasms."

Shorespan-007 is a Phase 3, randomized, double-blind, active comparator-controlled clinical trial (NCT06456346) assessing bomedemstat in comparison to the current standard chemotherapy, hydroxyurea, for ET patients who have not previously undergone cytoreductive therapy. Approximately 300 patients worldwide will be recruited for the trial. 

The primary outcome measure is the durable clinicohematologic response rate (CHR). Important secondary outcomes include the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) individual fatigue symptom item score, the Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a total fatigue score, and the MFSAF v4.0 total symptom score. Other secondary outcomes include the duration of hematologic remission, event-free survival, and the rate of disease progression.

As previously disclosed, bomedemstat is also being explored in Shorespan-006, another Phase 3, global, randomized, open-label, active comparator-controlled trial (NCT06079879), examining bomedemstat against the best available therapy for roughly 300 ET patients who show inadequate response to or intolerance of hydroxyurea.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of August 30, 2024, there are 70 investigational drugs for the KDM1A targets, including 82 indications, 59 R&D institutions involved, with related clinical trials reaching 85, and as many as 3117 patents.

Bomedemstat is a small molecule drug designed to target KDM1A and is being developed by Imago BioSciences, Inc. The drug is intended to address therapeutic areas such as neoplasms, hemic and lymphatic diseases, other diseases, and respiratory diseases. Its active indications include polycythemia vera, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis, thrombocythemia, essential, myelofibrosis, extensive stage small cell lung cancer, refractory acute myeloid leukemia, and relapsing acute myeloid leukemia.

图形用户界面, 文本, 应用程序

描述已自动生成

Cantargia announces schedules for nadunolimab trials in leukemia and triple negative breast cancer
Latest Hotspot
3 min read
Cantargia announces schedules for nadunolimab trials in leukemia and triple negative breast cancer
30 August 2024
Cantargia (Cantargia AB, Nasdaq Stockholm: CANTA) has updated the anticipated schedules for nadunolimab clinical studies.
Read →
Centessa Pharmaceuticals Presents Key Data on ORX142, a Novel OX2R Agonist, from Non-Human Primate Study
Latest Hotspot
2 min read
Centessa Pharmaceuticals Presents Key Data on ORX142, a Novel OX2R Agonist, from Non-Human Primate Study
30 August 2024
Centessa Pharmaceuticals Unveils Late-Breaking Poster on Non-Human Primate Data for ORX142, a New Orexin Receptor 2 (OX2R) Agonist.
Read →
Find Therapeutics Receives FDA Approval for Phase 1 Trial of FTX-101 in Chronic Optic Neuropathy
Latest Hotspot
2 min read
Find Therapeutics Receives FDA Approval for Phase 1 Trial of FTX-101 in Chronic Optic Neuropathy
30 August 2024
Find Therapeutics Announces FDA Approval for FTX-101 Phase 1 Clinical Trial in Chronic Optic Neuropathy Treatment.
Read →
European Commission Approves PADCEV and KEYTRUDA as First-Line Treatment for Advanced Urothelial Carcinoma
Latest Hotspot
3 min read
European Commission Approves PADCEV and KEYTRUDA as First-Line Treatment for Advanced Urothelial Carcinoma
30 August 2024
The European Commission has authorized the use of Astellas’ PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as an initial treatment for advanced urothelial carcinoma.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.